SLC34A2 typically has stable expression throughout ovarian cancer disease pathogenesis and treatment, as evidenced by the consistent SLC34A2 expression observed in longitudinal tissue samples (Banerjee et al., 2023b). This evidence concerns the gene SLC34A2 and ovarian carcinoma.